Elena Losina, an expert in the economic burden of osteoarthritis, discusses the high costs of living with OA, including direct healthcare expenses and lost productivity. She emphasizes the need for cost-effective treatments and efficient healthcare resource allocation to optimize outcomes for individuals with osteoarthritis.
Osteoarthritis patients face increased out-of-pocket costs for treatments like x-rays and surgeries.
Cost effectiveness analysis aids in evaluating treatment strategies based on health benefits and quality adjusted life years.
Deep dives
Economics of Osteoarthritis
The economic burden of osteoarthritis is significant, encompassing both direct medical costs related to treatment and other non-medical costs. Patients with osteoarthritis experience higher out-of-pocket expenses, including costs for x-rays, physical therapy, and surgeries. Moreover, individuals with osteoarthritis face substantial loss in productivity, impacting work attendance and efficiency. The episode delves into the economic consequences of osteoarthritis on individuals and society, emphasizing the need for understanding the cost effectiveness of treatments amidst healthcare resource limitations.
Costs and Quality Adjusted Life Years
Cost effectiveness analysis plays a pivotal role in assessing the value of different treatment strategies for osteoarthritis. This analysis combines health benefits and costs, often measured in quality adjusted life years (QALYs), to compare the outcomes of various approaches. The episode highlights the importance of determining the incremental cost effectiveness ratio to evaluate the impact on quality adjusted life expectancy. By distinguishing between high and low value care through cost effectiveness analysis, healthcare resources can be strategically allocated for optimal patient outcomes.
Challenges in Osteoarthritis Treatment
Certain treatments for osteoarthritis, such as physical activity and weight loss interventions, are identified as cost-effective strategies. Conversely, opioids are deemed not cost effective for osteoarthritis care due to their limited benefits. The discussion also addresses the role of arthroscopy in osteoarthritis treatment, recognizing the evolving evidence surrounding its effectiveness and the need for informed decision making.
Promoting High-Value Care
The podcast advocates for promoting high-value care and disinvestment in low-value care options for osteoarthritis treatment. It emphasizes the necessity of incorporating cost effectiveness considerations into treatment guidelines to ensure the allocation of healthcare resources towards effective and valuable interventions. The importance of patient education, shared decision-making, and a comprehensive approach to osteoarthritis management is underscored to improve patient outcomes and quality of life.
The economic burden due to osteoarthritis (OA) is massive and is the result of direct costs to the health care system, indirect costs to individuals living with OA, and the intangible costs of living with a chronic disabling condition. Compared to age and sex-matched peers, OA patients incur higher out of pocket health-related expenditures. People with OA also incur substantial costs due to lost productivity, including both absenteeism (days off work) and presenteeism (reduced self-reported productivity at work). As the burden of OA rises globally, so too will the economic burden
On this episode we discuss: the basic principles of osteoarthritis economics, average direct healthcare costs of living with osteoarthritis, total healthcare costs to the economy and much more.
Professor Elena Losina, Robert W. Lovett Professor of Orthopedic Surgery (Biostatistics) at Harvard Medical School, is an internationally recognized investigator in the epidemiology and outcomes of musculoskeletal disorders. She is a Director of the Policy and Innovation eValuation in Orthopedic Treatments (PIVOT) Center and co-Director of the Orthopaedic and Arthritis Center for Outcomes Research (OrACORe) and is a Principal Investigator of the Methodology Core of the Robert Brigham Multidisciplinary Clinical Research Center at Brigham and Women’s Hospital, Boston, MA. Dr. Losina has published over 300 peer-reviewed articles. Dr. Losina leads an NIH funded multi-sited project to conduct health policy evaluations related to surgical and non-surgical management of knee osteoarthritis. She is recognized internationally for her expertise in melding rigorous clinical research methodologies across multiple clinical disciplines, from orthopedics and osteoarthritis to global health.
If you enjoyed this episode, don't forget to subscribe to learn more about osteoarthritis from the world's leading experts! And please let us know what you thought by leaving us a review!